Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy

Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced positive data from the laboratory of Eduardo Marbán, M.D., Ph.D., Capricor’s Scientific Advisory Board Chairman and the Director of the Cedars-Sinai Heart Institute.

Read More

Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced that it has initiated dosing in a clinical study of eteplirsen, the Company’s lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in patients who are non-ambulant or who have advanced DMD and don’t meet a minimum 6-minute walk test score at baseline.

Read More

TACT TREAT–NMD Review

  Last weekend, I had the honor, along with Dr. Mike Kelly, CureDuchenne’s Chief Scientific Officer, and other TACT members, to review Duchenne research projects. CureDuchenne was able to look […]

Read More

Sarepta Therapeutics Announces Regulatory Update on Eteplirsen

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its planned New Drug Application (NDA) submission for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

Read More